Until recently, the use of Se-methylselenocysteine (MSC) as selective modulator of the antitumor activity and selectivity of anticancer drugs including irinotecan, a topoisomerase I poison, had not been evaluated. Therapeutic synergy between MSC and irinotecan was demonstrated by our laboratory in mice bearing human squamous cell carcinoma of the head and neck tumors. In FaDu xenografts, a poorly differentiated tumorexpressing mutant p53, the cure rate was increased from 30% with irinotecan alone to 100% with the combination of irinotecan and MSC. Cellular exposure to cytotoxic concentration of SN-38, the active metabolite of irinotecan (0.1 lM) alone and in combination with noncytotoxic concentration of MSC (10 lM) did not result in additional enhancement of chk2 phosphorylation and downregulation of specific DNA replication-associated proteins, cdc6, MCM2, cdc25A, nor increase in PARP cleavage, caspase activation and the 30-300 kb DNA fragmentation induced by SN-38 treatment. MSC did not alter significantly markers associated with apoptosis, nor potentiate irinotecaninduced apoptosis. These results indicate that apoptosis is unlikely to be one of the main mechanism associated with the observed in vivo therapeutic synergy. In contrast, significant downregulation of cyclooxygenase-2 (COX-2) expression and activity was observed in the cells exposed to SN-38 in combination with MSC compared to SN-38 alone. Moreover, the inhibition of PGE 2 production was also observed in the cells treated with the combination as compared with SN-38 alone. Analysis of tumor tissues at 24 h after treatment with synergistic modality of irinotecan and MSC revealed significant downregulation of COX-2, inducible nitric oxide synthase (iNOS) and hypoxia-induced factor-1a expression (HIF 1a). Moreover, decreased microvessel density was observed after irinotecan treatment with the addition of MSC. These results suggest that observed therapeutic synergy correlates with the inhibition of neoangiogenesis through the downregulation of COX-2, iNOS and HIF-1a expression.
Introduction
Although irinotecan, a topoisomerase I poison, is clinically approved for the treatment of patients with metastatic colorectal cancer, the treatment is associated with limited therapeutic efficacy and selectivity. Thus, a new approach is needed to improve the therapeutic efficacy of this agent and to delineate associated mechanisms.
Selenium-containing compounds are essential dietary trace elements being evaluated clinically as preventive agents in patients with various solid tumor malignancies. The therapeutic use of selenium as a selective modulator of the antitumor activity of anticancer drugs, however, has not been evaluated. Studies in our laboratory have demonstrated that Se-methylselenocysteine (MSC) and Selenomethionine (SLM) are highly selective modulators of the therapeutic activity and selectivity of anticancer drugs in a variety of human tumor xenografts . Mechanistically, selenium is a multitargeting agent that enhances apoptosis (Lu, 2001; Zhou et al., 2003; Apostolou et al., 2004) , and inhibits angiogenesis (Jiang et al., 1999; Lu and Jiang, 2001) , among many other effects and is a potent antioxidant as well . Consistent with published reports, our results demonstrate that the observed enhancement of the activity of irinotecan by MSC against human squamous cell carcinoma of the head and neck (HSCCHN) tumors is associated with increased chk2 phosphorylation at Thr 68 and downregulation of specific DNA replication-associated proteins resulting in the induction of 30-300 Kb DNA fragmentation, and PARP cleavage and activate caspase-3 . In contrast, our preliminary data indicated that no significant changes in molecular markers associated with apoptosis were observed in FaDu cells and xenografts cotreated with irinotecan and MSC. These results suggest that the potentiation of irinotecan activity by MSC is associated with mechanisms other than apoptosis.
Cyclooxygenase-2 (COX-2), is a key enzyme required to convert arachidonic acid to prostaglandins (PGs), is believed to be important in cancer development and angiogenesis (Chapple et al., 2002; Chang et al., 2004; Merchan et al., 2005) . A transgenic mouse model induced mammary tumors with increased concentrations of PGE 2 (Murakami et al., 2003; Chang et al., 2004) . PGE 2 stimulates angiogenesis by upregulating proangiogenic factors such as VEGF, which increase the supply of oxygen and nutrients to the tumor (Fukumura et al., 1998; Jones et al., 1999) .
Increasing nitric oxide (NO) concentration causes an increase in COX-2 expression (Park et al., 2003) . NO synthase (iNOS) is an inducible enzyme that after activation, leads to the prolonged elevation of NO from L-arginine (Park et al., 2003) . The constitutive expressions of both iNOS and COX-2 in various cancers suggest there will be a NO increase with elevated COX-2 activity (Rajnakova et al., 2001; Park et al., 2003) . Furthermore, experimentally inhibiting or promoting COX-2 expression has been reported to alter COX-2 mRNA synthesis (Park et al., 2003) . Additionally, inhibitors of NOS have been shown to decrease COX-2 expression demonstrating that COX-2 can be directly upregulated by NO (Wink et al., 1998; Surh et al., 2001; Park et al., 2003) . The transcription factors nuclear factor kappa B (NF-kB), AP-1 and C/EBP may also be involved (Chen et al., 2000; Chun et al., 2004) . It has been reported that SLM influences the transcription of COX-2 through NF-kB (Cherukuri et al., 2005) . It is also reported that NF-kB suppression by anti-inflammatory agents reduces both COX-2 and iNOS (Jiang et al., 2004; Ahn et al., 2005) . Further studies to define more precisely the role of NO in COX-2 regulation in cancer are warranted. Some tumor cells that lack COX-1 and -2 produce factors which stimulate angiogenesis (Tsujii et al., 1998) , implying the existence of alternative angiogenic pathways. Hypoxia is a major initiator of angiogenesis that induces a wide variety of genes by activating transcription factor hypoxia-induced factor-1a expression (HIF-1a) (Maxwell et al., 1997; Lando et al., 2002) , suggesting the role of HIF-1a as a transcriptional activator of COX-2. As our preliminary studies indicate that irinotecan and MSC inhibits angiogenesis, we hypothesized that the antiangiogenic action of the irinotecan and MSC may be mediated, at least in part by a decrease in HIF-1a expression. In the present study, we investigated COX-2 and HIF-1a. Owing to the potential role of COX-2, iNOS and HIF-1a as regulators of angiogenesis, we studied their relationship to the modulation of irinotecan sensitivity by MSC.
Results

Enhancement of antitumor activity of irinotecan by MSC
The data in Figure 1 demonstrate the kinetics of antitumor activity of irinotecan modulated by a nontoxic dose of MSC in FaDu xenografts. The data in Figure 1a indicate that complete tumor response in the FaDu xenografts is achieved within 1-2 weeks after termination of 4 weeks of treatment with irinotecan and MSC. Data not shown indicate that optimal therapeutic enhancement by MSC is dose dependent. The effect of MSC schedule on the antitumor activity of irinotecan at its MTD (100 mg/kg/week Â 4) in nude mice bearing human FaDu tumor xenografts were also evaluated. The data summarized in Figure 1b indicate that the cure rate in FaDu xenografts increased from 30 to 100% but only when MSC was administered orally daily for 7 days prior to and concurrently with the weekly dose of irinotecan. In contrast, simultaneous coadministration of MSC and irinotecan did not enhance the 30% complete tumor regression achieved with irinotecan alone. These data support the hypothesis that enhancement of the antitumor activity of irinotecan by MSC is dose-and schedule dependent. The maximum tolerated dose (MTD) of irinotecan alone is 100 mg/kg/ week Â 4 and in combination with MSC is 200 mg/kg/week Â 4. Antitumor activity (cure rate) of the MTD of irinotecan (100 mg/ kg/week Â 4) alone and in combination with MSC (0.2 mg/mouse/ day Â 28). Five mice/group were used and repeated three times.
MSC does not potentiate caspase-3 activation, PARP cleavage, DNA fragmentation or apoptosis induced by SN-38 First, we determined whether the alterations of chk2 phosphorylation and cdc6 expression were associated with the increased response to SN-38 by MSC in FaDu cells. The data in Figure 2a indicate that MSC did not further potentiate the changes in chk2, cdc6, MCM2, cdc25A expression or phosphorylation. The data in Figure 2b and c show that MSC did not enhance caspase-3 activation, PARP cleavage, or apoptotic 30-300 Kb DNA fragmentation.
To investigate the downstream effect of the induction of DNA double strand breaks further, the percentage of apoptotic cells was quantitated in cytospins using the TUNEL assay (Figure 3a) . Beginning 24 h after treatment with SN-38 a higher percentage of apoptotic cells could be detected (control: 0.25%, 24 h: 7.072.7%, 48 h: 16.573.0%). However, the addition of MSC did not potentiate SN-38-induced apoptosis.
To evaluate the in vivo effects of MSC on irinotecaninduced apoptosis, mice bearing FaDu tumor xenografts were treated with the MTD of MSC daily for 7 days prior to and concurrently with irinotecan, and tumor samples were removed on days 1, 3, 5 and 7 after the first dose of irinotecan. The data in Figure 3b indicate that while irinotecan induces significant levels of apoptosis, treatment with MSC produced no significant increase in these levels. Collectively, these results indicate that the alteration of molecular markers and DNA fragmentation associated with apoptosis may not be the critical mechanism associated with the observed synergy between MSC and SN-38 in FaDu cells.
MSC had no effect on Akt expression or phosphorylation, but downregulates COX-2 expression in vitro The PI3K-Akt signaling pathway has recently been shown to promote angiogenesis by promoting endothelial cell survival and migration (Dimmeler and Zeiher, 2000) . Therefore, we postulated that Akt activation may correlate with the observed antiangiogenic effect MSC has on SN-38-treated tumor cells. In vitro results (Figure 4a ) indicate that MSC had no direct effect on Akt expression or phosphorylation. Moreover, MSC downregulates the observed increase in COX-2 level induced by SN-38 (Figure 4b ). These results suggest the possibility that the observed in vivo antitumor synergy between MSC and irinotecan may be due to the inhibition of angiogenesis through COX-2 signaling, rather than the PI3K-Akt signaling pathways. Figure 2 Chk2 phosphorylation and cdc6 expression (a), caspase-3 activation and PARP cleavage (b) and DNA fragmentation (c) induced by SN-38 with or without MSC. Cells were treated with 10 mM MSC for 24 h in the presence of 0.01 U/ml METase, followed by 2 h exposure to 0.1 mM SN-387MSC, and then reincubated with drug-free medium or medium with MSC for an additional 24 and 48 h. Cell lysates for Western blot analysis were prepared as described under Materials and methods. b-Actin serves as a loading standard. Blots were representative of results from three separate experiments. Dashes to the right in (b) indicate the size in kilodaltons of the unprocessed and cleaved forms of PARP. Determination of DNA fragmentation was carried out also as described in Materials and methods. DNA ladder of 1 Kb and megabase I DNA standards are suitable for sizing double-strand DNA from 0.001 to 1.9 Mb.
Celecoxib in combination with SN-38 downregulates COX-2 expression
To further assess the role of COX-2 in cytotoxic synergy between MSC and irinotecan, preliminary in vivo studies were carried out to determine the effects of a COX-2 inhibitor celecoxib on the cure rate of FaDu xenografts treated with irinotecan. Celecoxib (50 mg/kg) was administered daily for 3 days prior to and 2 days after weekly Â 4 irinotecan. Results indicate that 70% of xenografts were cured compared with 30% with irinotecan alone (data not shown). These results support the role of COX-2 expression and activation in the synergy observed between MSC and irinotecan in FaDu xenografts. In vitro results ( Figure 4c ) showed a significant downregulation of COX-2 expression was seen in the FaDu cells treated with SN-38 and celecoxib.
MSC inhibits SN-38-induced COX-2 enzymatic activity
To further support the role of COX-2 activation in inhibiting VEGF-dependent angiogenesis, we measured COX-2 enzymatic activity in FaDu cells exposed to SN-38 with and without MSC. Data in Figure 5 reveal that COX-2 enzymatic activity increased from 29.9 to 140.9 nmol/min/mg after SN-38 exposure. When MSC was added COX-2 activity was drastically reduced from 140.9 to 46.1 nmol/min/mg in FaDu cell lysates (Po0.05). These results indicated that the inhibition of SN-38-induced COX-2 expression and activity by MSC was associated with the inhibition of angiogenesis due to the synergy between MSC and irinotecan.
MSC inhibits SN-38-mediated induction of PGE 2 synthesis
To determine whether increased COX-2 synthesis was associated with increased formation of PGs, we evaluated PGE 2 release in response to SN-38 with or without MSC. We measured PGE 2 release into the medium 24 or 48 h after the addition of SN-38 or SN-38 and MSC. Data in Figure 6 show that PGE 2 release induced by SN-38 increased from 144 to 604 pg/ml (4.2-fold) over a 48 h period compared with controls. MSC downregulates the observed increase in PGE 2 release from 604 to 332 pg/ml in FaDu cells exposed to SN-38 and MSC compared with SN-38 alone (Po0.001). These results are consistent with the immunoblot analysis of COX-2 and its enzymatic activity assay in response to SN-38 and SN-38 and MSC as shown in Figures 4b and 5 , indicating that the inhibited formation of PGE 2 corresponded to the decrease in COX-2 expression and activation.
MSC downregulates irinotecan-induced COX-2, iNOS and HIF-1a expression in vivo Based on in vitro results, we postulated that the observed in vivo therapeutic synergy between MSC and irinotecan might be explained on the basis of similar molecular alterations. Mice bearing FaDu xenografts were treated daily with the MTD of MSC and irinotecan. Tumor samples were removed 5 days after the first dose of irinotecan. Samples obtained from individual mice were analysed for COX-2, iNOS and HIF-1a expression (Figure 7 ). Data in Figure 7a indicate that MSC downregulates the expression of COX-2 induced by irinotecan. Densitometric analysis revealed a significant inhibition of COX-2 expression in xenografts exposed to irinotecan and MSC compared with irinotecan alone (P ¼ 0.016).
Owing to reports suggesting that iNOS and COX-2 are important in increasing neoangiogenesis in animal models and human tumors (Gallo et al., 2002; Cianchi et al., 2004) , we evaluated the role of iNOS expression in drug response and modulation of neoangiogenesis in vivo. The same specimens used in Figure 7a were subjected to Western blot analysis for iNOS expression. Data in Figure 7b indicate that MSC significantly inhibits the level of iNOS expression induced by irinotecan. Densitometric analysis confirmed the observed results (P ¼ 0.035).
Previous studies demonstrated that VEGF expression appears to be regulated by dual interdependent mechanisms involving HIF-1a directly and indirectly through NF-kB-mediated COX-2 expression (Jung et al., 2003; Pichiule et al., 2004) . Thus, we hypothesized that inhibition of COX-2 expression in xenografts exposed to irinotecan in combination with MSC may be accompanied by inhibition of HIF-1a expression. To test this hypothesis, HIF-1a levels were determined in the FaDu xenografts. Data in Figure 7c indicate that MSC significantly inhibits the level of HIF-1a expression induced by irinotecan. Densitometric analysis revealed that HIF-1a expression was significantly inhibited in FaDu xenografts exposed to irinotecan and MSC compared with irinotecan alone (P ¼ 0.031). Figure 8 summarize changes in average microvessel density in the FaDu xenografts after treatment with irinotecan with and without MSC. Enhanced microvessel density observed after irinotecan treatment decreased when MSC was added, reducing the level to near the level of untreated controls. Although the increased microvessel density in the irinotecantreated group could partially be explained by the tumor weight decrease (data not shown) due to direct tumor cell kill, accounting for the same effects in the irinotecan and MSC group would bring the microvessel density level for this group significantly closer to that of untreated controls. This is an indication that MSC reduces microvessel density and that the decrease in in vivo microvessel density is associated with the antitumor synergy of irinotecan and MSC in the FaDu tumor xenografts.
MSC decreases microvessel density induced by irinotecan Data in
Discussion
Selenium is a potent cancer preventive agent in animal model systems, and may also prevent cancer in humans (Medina and Morrison, 1988; Ganther, 1999; Reid et al., 2002) . Although recent studies have focused on the chemopreventive activity of selenium, our experimental studies in cell culture and animal models demonstrate that MSC can potentiate the activity of topoisomerase I poisons in vitro and in vivo Yin et al., 2004) . Since treatment with SN-38 and MSC increases chk2 phosphorylation at Thr 68 , downregulates DNA replication-associated proteins cdc6, MCM2 and cdc25A, and induces preapoptotic DNA fragmentation in another human head and neck carcinoma (A253), we hypothesized that the alterations of chk2 phosphorylation and cdc6 expression were associated with the increased response to SN-38 and MSC in the FaDu cells. Data in Figure 2 indicate that treating FaDu cells with the highest noncytotoxic concentrations of MSC activated by methioninase for 24 h prior to and during the 2 h exposure to SN-38 (IC 90 ) did not result in significant changes in chk2 phosphorylation, cdc6, MCM2, cdc25A, activation of caspase-3, Figure 7 Western blotting for COX-2 (a), iNOS (b) and HIF-1a (c) expression in FaDu xenografts exposed to irinotecan with or without MSC. Treatment was as described in Materials and methods and specimens were collected on day 5. Representative results out of three sets of experiments are shown in panel a. Densitometric analysis for relative expression levels of COX-2, iNOS, HIF-1a and b-actin was determined by scanning the films shown in panel a. Normalizing COX-2, iNOS and HIF-1a expression with b-actin indicated that COX-2, iNOS and HIF-1a expression was significantly lower in the FaDu xenografts treated with the combination than with irinotecan alone (P ¼ 0.016, 0.035 and 0.031, respectively).
PARP cleavage or the increase in 30-300 Kb DNA fragmentations. Since the appearance of DNA fragments ranging from 30 to 300 Kb is typically associated with apoptotic cell death (Oberhammer et al., 1993; Collins et al., 1997) , alteration of molecular markers and DNA fragmentation associated with apoptosis may not be the critical mechanism for the synergy observed between MSC and SN-38 in FaDu cells.
We suggest the possibility that the observed in vitro cytotoxic synergy between MSC and SN-38 might be due to the modulation of neoangiogenesis. Data in Figure 8 indicate that the enhanced microvessel density observed after irinotecan treatment decreased when MSC was added. These results suggest the possibility that the inhibition of neoangiogenesis in vivo may be associated with the antitumor synergy of irinotecan and MSC. Endothelial CD40 affects several steps important for angiogenesis, including cell proliferation, motility, and formation of vessel-like structures, through the PI3K/Akt signaling pathway Deregibus et al., 2003) , suggesting that Akt mediates angiogenesis. To confirm whether the inhibition of SN-38-induced angiogenesis involves Akt inactivation, we examined the effect of MSC on SN-38-induced Akt expression and phosphorylation. The results show no significant difference of Akt expression and phosphorylation in FaDu cells, when exposed to SN-38 with and without MSC. This suggests that the synergy observed with this combination is causing the inhibition of neoangiogenesis from a source other than the Akt signaling regulation pathways in the FaDu cells. Molecular, pharmacological and genetic studies of COX-2 function indicate a critical role for this molecule in neoangiogenesis and tumor progression (Liu et al., 2001; Muller-Decker et al., 2002; Iniguez et al., 2003) . Several inhibitors of COX-2 block neoangiogenesis in experimental tumors (Masferrer et al., 2000; Wei et al., 2004) . In order to investigate whether the observed cytotoxic synergy between MSC and SN-38 is involved in COX-2 signaling pathways, we examined the effect of MSC on COX-2 expression in vitro and in vivo. As shown in Figures 4b and 5 , MSC blocks the observed increase in COX-2 expression and activity induced by SN-38 in vitro. Further, MSC and SN-38 downregulate VEGF secretion in vitro as well (data not shown). These results suggest that the in vivo synergy observed between MSC and irinotecan might be due to the inhibition of angiogenesis by COX-2 signaling, rather than the PI3K-Akt signaling regulation pathway.
To further evaluate COX-2 as a modulator of cytotoxic synergy between MSC and irinotecan, we studied the effect of the selective COX-2 inhibitor celecoxib on the cure rate of FaDu xenografts treated with irinotecan in vivo and on the COX-2 expression induced by SN-38 in vitro. We found that celecoxib potentiated the cure rate from 30% with irinotecan alone to 70% cure rate with irinotecan and celecoxib combination. The cure rate of FaDu xenografts treated with celecoxib and irinotecan combination was less than that observed with MSC in combination with irinotecan. Similar to MSC, a significant downregulation of COX-2 expression was seen in the FaDu cells treated with the combination of SN-38 and celecoxib. Therefore, it seems that the antitumor effect potentiated by celecoxib is partly mediated through inhibition of the COX-2 enzyme. This observation supports our hypothesis (Figure 9 ) that the observed in vivo antitumor synergy between MSC and irinotecan, is at least partly due to the inhibition of COX-2 signaling. Recent data indicate that SLM works through NF-kB binding to inhibit the luciferase activity of COX-2 reporter constructs (Cherukuri et al., 2005) . Thus, it may be concluded that SLM inhibits the transcription of COX-2 by targeting the NF-kB transcription factor.
As mentioned in Introduction, COX-2 is influential in PGE 2 regulation (Chapple et al., 2002; Chang et al., 2004; Merchan et al., 2005) . Our results (Figure 6 ) show that MSC downregulates PGE 2 release in FaDu cells exposed to SN-38 and MSC compared with SN-38 alone, suggesting that COX-2 is the main source of the NO-stimulated increase in PGE 2 production. Our findings also suggest that increases in COX-2 activation and increased PGE 2 production might promote angiogenesis, these results are consistent with those of Cianchi et al. (2004) . Much evidence suggests that COX-2 and iNOS play important roles in cancer by promoting neoangiogenesis. The combined influence of COX-2 and iNOS on angiogenesis has been studied in human and animal tumors (Bing et al., 2001; Kisley et al., 2002; Cianchi et al., 2004) . We studied these two enzymes in the FaDu tumor. Our data revealed that iNOS expression was inhibited significantly in FaDu xenografts exposed to irinotecan and MSC compared with irinotecan alone. Coinhibition of COX-2 and iNOS expression in xenografts treated with irinotecan and MSC suggests that these two enzymes are common molecular targets, mainly through an antiangiogenic effect. Previous studies demonstrated that the proangiogenic molecule VEGF can be influenced by iNOS and COX-2 expression (Cianchi et al., 2001 (Cianchi et al., , 2003 . It also has been shown that NO production by activation of the NO/ cGMP pathway is required for the proangiogenic activity of VEGF (Ziche et al., 1993 (Ziche et al., , 1997 Cianchi et al., 2004) . MSC and SN-38 downregulates VEGF secretion, which indicates that the blockade of COX-2 and/or iNOS might lower VEGF and thus reduce angiogenesis (Cianchi et al., 2004) . Some anti-inflammatory agents inhibit both COX-2 and iNOS by suppressing NF-kB activation (Jiang et al., 2004; Ahn et al., 2005) , suggesting that the mechanism of the cytotoxic synergism of MSC and SN-38 is the reduction of COX-2 and iNOS gene expression by blocking NF-kB activation. Since HIF-1a mediates the transcriptional regulation of several genes involved in neoangiogenesis under hypoxic conditions it is conceivable that COX-2 and iNOS expression might be controlled by the same oxygen-dependent mechanism. Our data revealed significant inhibition of HIF-1a expression in the FaDu xenografts exposed to irinotecan and MSC, suggesting that HIF-1a may have an important role in controlling COX-2 and iNOS expression during hypoxia.
Schematic representation of target sites for the action of MSC alone and in combination with irinotecan is outlined in Figure 9 . Hypoxia is a basic stimulator of angiogenesis, through HIF-1a. An increase in HIF-1a increases VEGF transcription. In addition, HIF-1a influences other cellular processes that occur when normal oxygen levels prevail, such as the development of tumors, and the determination of cell death or survival. Under normoxic conditions, HIF-1a can be activated by other stimuli including the presence of cytokines, growth factors, and NO, produced through the induction of iNOS, important in angiogenesis (Gallo et al., 1998) . Increased NO could result in activation of COX-2, which leads to increased PGE 2 , HIF-1a and VEGF expression. Recent results by Rapisarda et al. (2004) indicate that the antitumor activity of Topotecan is associated with decreased HIF-1a protein, angiogenesis and HIF-1a target gene in tumor tissues. In addition, studies by Hussain et al. (2004) provided evidence that NO can suppress tumorigenesis. These reports and our results support the notion that increased iNOS, COX-2 and HIF-1a are involved in controlling neoangiogenic activity in tumors treated with MSC and irinotecan in combination. The flow chart in Figure 9 is nonexclusive and simplified for depicting the cascade of relevant events proposed for investigation. We hypothesize that MSC enhances the antitumor activity of irinotecan by inhibiting HIF-1a production directly and/or through inhibition of NO production and Figure 9 Potential mechanisms that lead to modulation of therapeutic synergy with MSC and irinotecan.
COX-2 activation leading to downregulation of PGE 2 expression.
Our in vitro and in vivo results suggest that therapeutic doses of MSC/irinotecan downregulate HIF-1a, NO production, COX-2 and VEGF expression, and this is associated with the inhibition of neoangiogenesis. Recent reports from our laboratory clearly demonstrated that the in vivo synergistic effect of MSC is not irinotecan specific, and it can be seen with other drugs as well, supporting the idea of a common antiangiogenic mechanism of MSC . These results will provide the rationale for evaluating the role of these markers individually and collectively in determining response to MSC/irinotecan combination therapy.
Materials and methods
Reagents and antibodies SN-38 (7-ethyl-10-hydroxycamptothecin) and irinotecan (PNU-101440E) were kindly supplied by Pharmacia Corporation (Kalamazoo, MI, USA). The injectable formulation of irinotecan was obtained by dissolving irinotecan (20 mg/ml), D-sorbitol (45 mg/ml; Sigma-Aldrich, St Louis, MO, USA), and D-lactic acid (0.9 mg/ml; Sigma-Aldrich) in doubledistilled water heated 80-901C for 10 min. The pH was adjusted to 3.5. The solution was sterile filtered and stored protected from light until administration. MSC was purchased from Sigma-Aldrich and dissolved in sterile saline at a concentration of 1 mg/ml. METase, the activating enzyme, at 0.01 U/ml was added to all MSC treatment in vitro.
The following antibodies were utilized: anti-AKT polyclonal antibody, anti-P-AKT (Ser473) polyclonal antibody, and cleaved caspase-3 (Asp175) (5A1) rabbit monoclonal antibody (Cell Signaling Technology Inc., Beverly, MA, USA), anti-COX-2 monoclonal antibody (Cayman Chemical, Ann Arbor, MI, USA), anti-iNOS (M-19) polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-HIF-1a monoclonal antibody (BD Biosciences Pharmingen, San Diego, CA, USA), and anti-Poly-(ADP-Ribose)-Polymerase (PARP) polyclonal antibody (Roche Diagnostics Corporation, Indianapolis, IN, USA). Anti-b-actin mAb (Sigma-Aldrich) was used to demonstrate equal protein loading. Rat antimouse primary mAb CD31 (BD Biosciences Pharmingen, San Diego, CA, USA) was applied in the immunohistochemical method to detect and count microvessels in the mouse xenografts.
Cell culture
The human squamous carcinoma of the HSCCHN cell line FaDu (41-HTB) was purchased from American Type Culture Collection (Rockville, MD, USA) and maintained as a monolayer in RPMI 1640 medium supplemented with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA, USA). The doubling time of the cells is 27 h and all treatments were carried out using exponentially growing cell cultures. The cell lines were free from mycoplasma as tested with the mycoplasma plus PCR primer set (Stratagene, Cedar Creek, TX, USA) every 2 months.
Tumorgenicity in nude mice
The exponentially growing human FaDu cells were established as a xenograft in female athymic nude mice (nu/nu, body weight, 20-25 g), 8-12 weeks of age, obtained from Harlan Sprague Dawley Inc., (Indianapolis, IN, USA) and kept five mice/cage with water and food ad libitum. Xenografts were initially established by implanting subcutaneously 10 6 cultured cells and passed several generations by transplanting B50 mg non-necrotic tumor tissues
Drug treatment
The treatment was initiated when tumors reached approximately 200 mg (7-8 days after tumor transplantation). Five mice were used for each experimental group and experiments were repeated at least twice. For the cotreatment studies with irinotecan, MSC was given 7 days before irinotecan therapy and administered daily by oral route at 0.2 mg/mouse/day. The irinotecan was administered by intravenous push. All of the studies were performed in accordance with Institutional Animal Care and Use Committee and under an approved Institute protocol.
Assays for antitumor activity Antitumor activity was assessed by maximum tumor growth inhibition (MTGI), which is mean tumor weight (MTW) of the treated group (TG) compared with the untreated control group (CG) at same time (most time is day 10-12 when CG was killed because the tumor reached about 2000 mg), which is calculated as MTGI ¼ (MTWTG-MTWCG)/MTWCG Â 100%. The tumor doubling time was defined as the mean time for the tumor to reach twice its initial weight (at treatment beginning, day 0). Tumor response was expressed as partial response when tumor weight was temporarily reduced by at least 50% compared with initial tumor size and as complete response when tumor was undetectable by palpation at site of transplant. Cure was defined as animal surviving with no tumor for at least 3 months after treatment, at which time the animals were killed. Under these conditions, all of the tumor cells were killed; otherwise, even if one single tumor cell survived treatment, it would have developed into a large tumor within 2-3 weeks after termination of therapy. The response rate was expressed as the percentage of animals in the group.
Protein extraction and Western blot analysis
Western blot was used to analyse protein expression in cell and xenograft extracts. Total proteins were isolated using approximately 5 Â 10 6 cells or 100 mg tissues lysed in lysing buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.5% SDS, 0.5% sodium deoxycholate, 0.5% Nonidet P40, 10 mM dithiothreitol, 1 mM PMSF and 0.4 TIU aprotinin). The protein concentration was quantified by the Bio-Rad DC protein assay (Bio-Rad, Hercules, CA, USA). In all, 50 mg of cell extract were loaded and separated on SDS-PAGE and then transferred onto a nitrocellulose membrane (Bio-Rad). Western blotting was performed with antibodies listed above, using the Renaissance chemiluminescence reagent kit (Perkin Elmer Life Science Products, Boston, MA, USA). Relative levels of protein expression were measured by using densitometry.
COX-2 enzyme activity analysis COX-2 activity was analysed in FaDu cell lysates using the COX activity assay kit from Cayman Chemical (Ann Arbor, MI, USA) following the manufacturer's instructions, similar to the method used by Pichiule et al. (2004) . Briefly, the peroxidase activity of COX was determined using N,N,N 0 ,N 0 -tetramethyl-p-phenylenediamine (TMPD) as the substrate, measured at 590 nm. Purified ovine COX-1 was used as the positive control and SC-560 (COX-1 inhibitor) and DuP-697 (COX-2 inhibitor) were used to distinguish between COX-2 and -1 activity. Total COX activity was measured and COX-2 activity was determined as the difference between total COX activity and COX-1 activity. The result was expressed as the rate of oxidation of TMPD in nmol/min/mg protein.
Measure PGE 2 levels by ELISA assay FaDu cells were cultured in six-well plates in 1.0 ml of medium and plated in triplicates for each experiment. Serum-starved cell supernatants for 24 h were collected and 50 ml of centrifuged supernatants were used for PGE 2 determination. The PGE 2 release in the medium was measured by ELISA assay using a PGE 2 EIA kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's instructions. A standard curve was developed simultaneously with standards ranging from 7.8 pg to 1000 pg/ml PGE 2 . Values of PGE 2 were expressed as pg/ml of media from the cells.
PFGE analysis for DNA fragmentation
The procedure for preparation of DNA plugs was a modification of that described by Schwartz and Cantor (1984) and Giaccia et al. (1991) , 1% agarose gels were prepared in 0.5 Â BRL TBE buffer (75 mM Tris, 25 mM boric acid and 0.1 mM EDTA, pH 8.9). Electrophoresis was carried out using Hex-A-Field horizontal gel electrophoresis apparatus (GIBCO-BRL), which contains a hexagonal array of electrodes having a reorientation angle of 1201. Electrophoresis was performed in TBE buffer at 141C with buffer circulation. Electrophoresis was carried out in one phase: 90 s pulse time, 16 h running time at 170 V with TBE buffer circulation at 141C. DNA ladder (1 kb) and megabase I DNA standards were used for sizing double-strand DNA from 0.001 to 1.9 Mb. Following electrophoresis, gels were stained with ethidium bromide and then photographed on a UV transilluminator.
In vitro and in vivo analysis for apoptosis Exponentially growing cells were exposed for 2 h to SN-38, washed once, and then maintained in drug-free medium for 24 or 48 h. Cells were harvested at the indicated time points. Approximately 5 Â 10 4 cells were used for cytospins using the Cytospin 3 from Shandon (Pittsburgh, PA, USA). Apoptosis was evaluated by morphology after conventional H&E staining. Nuclear condensation and fragmentation identified apoptotic cells. Apoptotic index was calculated as the percentage of apoptotic cells among 300 cells in randomly selected areas of the cytospins. The presence of apoptotic cells in vitro or in vivo were confirmed by terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling (TUNEL assay), according to the manufacturer's instructions (Apoptag in situ Apoptosis Detection kit, Invitrogen, Purchase, NY, USA) and as published earlier (Guo et al., 2000; Azrak et al., 2004) .
Immunohistochemical detection and quantitation of microvessels in FaDu xenografts
The tumors removed from nude mice were fixed in formalinfree IHC Zinc Fixative (BD Biosciences PharMingen, San Diego, CA, USA) overnight and then processed for paraffin sections. Immunohistochemical staining for mouse endothelial cells (tumor microvessels) were carried out as published earlier (Bhattacharya et al., 2004) using rat anti-mouse primary antibody CD31 in 10 mg/ml concentration for 1 h at room temperature. Biotinylated secondary antibody (anti-rat, BD Biosciences PharMingen) was used for 30 min followed by the streptavidin complex (Zymed Lab Inc., San Francisco, CA, USA) for 30 min.
All CD31-positive intratumoral microvessels were counted at Â 400, referred to as a high power field (HPF). Endothelial cells and vessels in connective tissue without tumor cells were not counted. Depending on the size of tumor, 30 microscopic fields on an average (range 10-68) were counted by an experienced pathologist (Dr To´th) with the vessels range of 194-2527 per tumor section. Average microvessel density/HPF Â 400 in various tumor groups are shown in Results.
Statistical analysis
Data are mean values of at least three replicate experiments and expressed as means7s.e. A P-value of o0.05 was considered statistically significant using unpaired two-tailed t-test for independent samples, with Welch correction applied.
